Zheng Xing Xing Ye Ri Bao·2025-11-27 09:06Market Overview - The biopharmaceutical sector experienced a decline of 0.52% on November 27, with Sangfor Biopharma leading the drop [1] - The Shanghai Composite Index closed at 3875.26, up 0.29%, while the Shenzhen Component Index closed at 12875.19, down 0.25% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Olin Biotech (688319) with a closing price of 25.49, up 4.98% and a trading volume of 103,300 shares, totaling 263 million yuan [1] - Rongchang Biopharma (688331) closed at 96.00, up 4.07% with a trading volume of 65,600 shares, totaling 623 million yuan [1] - Hualan Biological (301207) closed at 24.70, up 2.57% with a trading volume of 222,400 shares, totaling 538 million yuan [1] - Conversely, significant decliners included: - Sangfor Biopharma (688336) closed at 64.70, down 5.40% with a trading volume of 60,400 shares, totaling 400 million yuan [2] - Jindike (688670) closed at 29.32, down 5.11% with a trading volume of 155,900 shares, totaling 453 million yuan [2] - WanTai Biotech (603392) closed at 49.09, down 2.89% with a trading volume of 52,600 shares, totaling 260 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 251 million yuan from institutional investors, while retail investors experienced a net inflow of 229 million yuan [2] - Notable capital flows included: - Rongchang Biopharma had a net inflow of 64.13 million yuan from institutional investors, while retail investors saw a net outflow of 39.11 million yuan [3] - Olin Biotech experienced a net inflow of 7.37 million yuan from institutional investors, with retail investors facing a net outflow of 24.86 million yuan [3]